Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
27.17
-1.46 (-5.10%)
Jul 31, 2026, 12:08 PM EDT - Market open
Alto Neuroscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 263.76 | 176.48 | 168.23 | 82.55 | 48.34 | 25.71 |
Cash & Short-Term Investments | 263.76 | 176.48 | 168.23 | 82.55 | 48.34 | 25.71 |
Cash Growth | 64.08% | 4.91% | 103.79% | 70.75% | 88.07% | - |
Accounts Receivable | - | - | - | - | - | 1.5 |
Other Receivables | - | - | - | - | 0.33 | - |
Total Trade Receivables | - | - | - | - | 0.33 | 1.5 |
Other Current Assets | 5.36 | 1.23 | 1.11 | 2.84 | 0.54 | 0.48 |
Total Current Assets | 269.13 | 177.72 | 169.34 | 85.39 | 49.22 | 27.68 |
Net Property, Plant & Equipment | 6.3 | 6.13 | 7.7 | 1.11 | 1.17 | 1.06 |
Other Long-Term Assets | 0.84 | 0.84 | 0.5 | 0.13 | 0.46 | 0.05 |
Total Assets | 276.26 | 184.69 | 177.54 | 86.63 | 50.85 | 28.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.37 | 1.88 | 1.58 | 1.07 | 1.61 | 0.6 |
Accrued Expenses | 7.61 | 8.86 | 8.43 | 4.54 | 3.95 | 1.21 |
Current Portion of Long-Term Debt | 2.14 | 0.59 | - | - | - | - |
Total Current Liabilities | 13.12 | 11.33 | 10.01 | 5.61 | 5.56 | 1.81 |
Long-Term Debt | 13.89 | 16.17 | 10.25 | 9.86 | 9.47 | - |
Long-Term Leases | 3.56 | 3.82 | 4.52 | - | - | - |
Other Long-Term Liabilities | 2.34 | 2.23 | 1.3 | 1.35 | 2 | 1.3 |
Total Long-Term Liabilities | 19.78 | 22.22 | 16.07 | 11.21 | 11.47 | 1.3 |
Total Liabilities | 32.89 | 33.55 | 26.08 | 16.82 | 17.03 | 3.11 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | - | - | - |
Additional Paid-in Capital | 471.22 | 352.75 | 289.95 | 5.37 | 2.3 | 0.49 |
Accumulated Other Comprehensive Income | 0.01 | 0.02 | -0.1 | -0.08 | -0.05 | -0.02 |
Retained Earnings | -227.87 | -201.63 | -138.4 | -76.97 | -40.66 | -12.95 |
Total Common Shareholders' Equity | 243.37 | 151.14 | 151.46 | -71.67 | -38.41 | -12.48 |
Minority Interest | - | - | - | 141.48 | 72.24 | 38.16 |
Shareholders' Equity | 243.37 | 151.14 | 151.46 | 69.81 | 33.83 | 25.69 |
Total Liabilities & Equity | 276.26 | 184.69 | 177.54 | 86.63 | 50.85 | 28.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 19.58 | 20.58 | 14.77 | 9.86 | 9.47 | 0 |
Net Cash (Debt) | 244.19 | 155.9 | 153.46 | 72.69 | 38.88 | 25.71 |
Net Cash Growth | 79.02% | 1.59% | 111.12% | 86.96% | 51.25% | - |
Net Cash Per Share | 8.05 | 5.40 | 6.24 | 19.48 | 11.28 | 10.65 |
Book Value | 243.37 | 151.14 | 151.46 | -71.67 | -38.41 | -12.48 |
Book Value Per Share | 8.03 | 5.24 | 6.16 | -19.21 | -11.15 | -5.17 |
Tangible Book Value | 243.37 | 151.14 | 151.46 | -71.67 | -38.41 | -12.48 |
Tangible Book Value Per Share | 8.03 | 5.24 | 6.16 | -19.21 | -11.15 | -5.17 |